November 7, 2025 — Leads & Copy — Dr. Adrian Bot, a biopharmaceutical founder and scientist, has joined Immuthera’s Board of Directors and will also serve as Scientific Advisor of PolTREG S.A., to support the company with his experience in commercializing cell therapies.
Immuthera, a U.S.-based subsidiary of PolTREG S.A., is focused on regulatory T cell technologies. PolTREG S.A. is a leader in innovative immune therapies.
Dr. Bot has 27 years of experience in the U.S. biopharmaceutical industry, including discovery, preclinical and clinical development, translational medicine, and product lifecycle management in a commercial setting. Over half of his career has been spent developing CAR T cell products.
Dr. Bot was the founding CSO and EVP of R&D for Capstan Therapeutics, a company developing in vivo mRNA-based CAR-T therapies. He helped secure $165 million in financing for Capstan and participated in its sale to AbbVie for $2.1 billion in 2025.
Dr. Bot also held leadership positions at Kite Pharma, where he contributed to the success of Yescarta and Tecartus, CAR-T cell therapies for Oncology. Gilead acquired Kite Pharma for $11.9 billion in 2017.
Dr. Bot obtained his M.D. from the University of Medicine and Pharmacy, Timisoara, Romania, in 1993, and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998. He was also a Guest Scientist at Scripps Research Institute in La Jolla, California, and has authored or co-authored over 100 scientific publications.
According to the press release, Dr. Bot has experience in the development and commercialization of therapies integrating gene medicines and cellular technologies, participating in numerous financing rounds and two major acquisitions as Chief Scientific Officer. Capstan’s primary assets included its in vivo CAR-T therapy candidate, CPTX2309, and its patented lipid nanoparticle platform technology, used for mRNA delivery and cell engineering. Yescarta was the second CAR-T therapy approved by the FDA and the first for Non-Hodgkin’s lymphoma.
Dr. Bot commented, “PolTREG is a global leader in the development of T-regulatory cell products with over 12 years of clinical experience in over 100 patients… I am very excited to help Immuthera and PolTREG S.A. advance and commercialize transformative therapies based on engineered Tregulatory cells, for patients in need. We are traversing an inflexion point for the field and I have high confidence in the leadership team under Dr. Piotr Trzonkowski as they are well positioned for a US expansion.”
Prof. Piotr Trzonkowski, founder and CEO of PolTREG S.A. said, “Dr. Bot is a seasoned, accomplished, and well respected leader in the evolving field of cell and gene therapies… We share the vision that T regulatory cells, reinforced by the recent Nobel Prize awarded for their discovery, represent the next frontier in cell therapies for patients with autoimmunity and other disease indications. Dr. Bot’s experience and innovative scientific and business approach will be invaluable on our journey to ultimately commercialize Tregulatory cell therapies.”
PolTREG is intensifying its presence in the American market and its partners include Kinexum Services LLC and Antion Biosciences.
PolTREG’s lead product, PTG-007, an autologous Treg treatment for early-onset Type-1 Diabetes (T1D), is ready for Phase 2/3 clinical testing, for which the company is seeking a partnership.
More information about Immuthera can be found at https://immuthera.bio/ and PolTREG S.A. at https://poltreg.com/pl/
Contact: ir@poltreg.com
Source: Immuthera
